QUINOXALINE-2,3-DIONE: CHEMICAL STRUCTURE, SYNTHETIC STRATEGIES, STRUCTURE–ACTIVITY RELATIONSHIP, REACTIVITY, AND PHARMACOLOGICAL ACTIVITIES

Authors

  • Dr.K.Manisha Department of Pharmacypractice, Research Guide, Vaageswari College of Pharmacy, Karimnagar, Telangana, India
  • Mayank Bhartwaj Department of Pharmacypractice, Research Guide, Vaageswari College of Pharmacy, Karimnagar, Telangana, India
  • Akash Gautam Department of Pharmacypractice, Research Guide, Vaageswari College of Pharmacy, Karimnagar, Telangana, India
  • D. Venket Sai Department of Pharmacypractice, Research Guide, Vaageswari College of Pharmacy, Karimnagar, Telangana, India

DOI:

https://doi.org/10.22270/ajprd.v14i2.1743

Abstract

Type 2 Diabetes Mellitus (T2DM) is increasingly being diagnosed among young individuals due to lifestyle changes and genetic predisposition. C-peptide, a by-product of insulin synthesis, serves as a reliable marker of endogenous insulin secretion and β-cell function.

This study was conducted to evaluate the role of C-peptide estimation in newly diagnosed Type 2 diabetic patients. A prospective observational study was carried out on 200 patients aged 18–35 years. Data including fasting blood sugar, postprandial blood sugar, HbA1c, and C-peptide levels were collected and analyzed.

The results showed that patients with higher C-peptide levels had better glycemic control, while those with lower levels required early insulin therapy. A negative correlation was observed between HbA1c and C-peptide levels.

The study concludes that C-peptide estimation plays an important role in assessing β-cell function and guiding treatment strategies in young Type 2 diabetic patients.

 

Downloads

Download data is not yet available.

References

Leighton E, Sainsbury CA, Jones G C.A Practical Review of C-Peptide Testingin Diabetes. DiabetesTher. 2017.

Maddaloni E et al. C-peptide determination in the diagnosis of type of diabetes and its management. Diabetes Obes Metab. 2022.

Jones AG, Hattersley AT. The clinicalutility of C-peptide measurement in diabetes care. Diabet Med. 2013.

LinYetal. Exploring the potential role of C-peptide in type 2 diabetes management. Diabet Med.2025.

Chenetal. C-peptide and risk of diabetes-related complications. Front Endocrinol.2023.

IJAM Study.Clinical profile of young-onset diabetesin India. IntJ Adv Med.

American Diabetes Association. Classification and Diagnosis of Diabetes. Diabetes Care.2024.

De Fronzo RA, FerranniniE, GroopL, etal.Type 2 diabetes mellitus. Nat Rev Dis Primers.2015.

Fourlanos S, Dotta F,Greenbaum CJ,etal. Latent autoimmune diabetes in adults. Diabetes Care.2005.

Hattersley AT, Patel KA. Maturity-onset diabetes of the young: clinical characteristics, diagnosis and management. Lancet Diabetes Endocrinol. 2017.

Holt RIG, De Vries JH, Hess-Fischl A, etal.The management of diabetes. Lancet.2021.

Buchanan TA, Xiang AH. Gestational diabetes mellitus. Jclin Invest. 2005.

International Diabetes Federation. IDF Diabetes Atlas,10th ed. 2021.

HillierTA, Pedula KL. Youth-onset Type 2 diabetes. Diabetes Care. 2003.

Anjana R Metal. Diabetes prevalence in India. Lancet Diabetes Endocrinol. 2017.

Yajnik CS. Insulin resistance in India.Natl MedJ India.2018.

Narayan KM Vetal. Global NCD burden. N Engl J Med.2010.

Mohan Vet al.Young-onset diabetes in India. Indian J Endocrinol Metab.2014.

Mc Carthy MI.Genetics of type 2 diabetes. Lancet. 2010.

De Fronzo RA. Pathogenes is of Type 2 diabetes mellitus. Med Clin North Am. 2004.

Published

2026-06-19

How to Cite

Dr.K.Manisha, Mayank Bhartwaj, Akash Gautam, & D. Venket Sai. (2026). QUINOXALINE-2,3-DIONE: CHEMICAL STRUCTURE, SYNTHETIC STRATEGIES, STRUCTURE–ACTIVITY RELATIONSHIP, REACTIVITY, AND PHARMACOLOGICAL ACTIVITIES. Asian Journal of Pharmaceutical Research and Development, 14(2), 217–221. https://doi.org/10.22270/ajprd.v14i2.1743

Issue

Vol. 14 No. 2 (2026): Volume 14 Issue 2 March- April. 2026

Section

Case Report

Copyright (c) 2026 Dr.K.Manisha, Mayank Bhartwaj, Akash Gautam, D. Venket Sai

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.

Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).